CATALOGO DEI PRODOTTI DELLA RICERCA

MELISI, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.448
EU - Europa 4.211
AS - Asia 3.628
SA - Sud America 524
AF - Africa 57
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 5
Totale 13.885
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.378
CN - Cina 1.454
SG - Singapore 1.365
GB - Regno Unito 1.154
IT - Italia 525
SE - Svezia 507
BR - Brasile 457
HK - Hong Kong 425
DE - Germania 424
RU - Federazione Russa 385
IE - Irlanda 363
FR - Francia 349
FI - Finlandia 248
KR - Corea 87
VN - Vietnam 86
UA - Ucraina 74
CA - Canada 46
NL - Olanda 39
JP - Giappone 32
AT - Austria 28
IN - India 24
BD - Bangladesh 22
ID - Indonesia 22
TR - Turchia 21
BE - Belgio 20
ZA - Sudafrica 18
PL - Polonia 17
TG - Togo 17
AR - Argentina 14
MX - Messico 14
IQ - Iraq 13
CH - Svizzera 12
AU - Australia 11
CL - Cile 11
CZ - Repubblica Ceca 11
EC - Ecuador 11
SA - Arabia Saudita 11
ES - Italia 10
PT - Portogallo 9
PY - Paraguay 9
VE - Venezuela 9
IR - Iran 8
PK - Pakistan 7
MA - Marocco 6
PE - Perù 6
JO - Giordania 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
BG - Bulgaria 4
EU - Europa 4
KG - Kirghizistan 4
LK - Sri Lanka 4
LT - Lituania 4
UZ - Uzbekistan 4
AL - Albania 3
AM - Armenia 3
BY - Bielorussia 3
CO - Colombia 3
DK - Danimarca 3
DZ - Algeria 3
EE - Estonia 3
HN - Honduras 3
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
RO - Romania 3
SN - Senegal 3
UY - Uruguay 3
EG - Egitto 2
GE - Georgia 2
HU - Ungheria 2
IL - Israele 2
LV - Lettonia 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PH - Filippine 2
PS - Palestinian Territory 2
QA - Qatar 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BO - Bolivia 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GI - Gibilterra 1
HT - Haiti 1
IM - Isola di Man 1
KH - Cambogia 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
RE - Reunion 1
Totale 13.881
Salva come PNG Salva come JPEG
Città #
Southend 1.033
Chandler 841
Dallas 622
Singapore 614
Jacksonville 488
Ashburn 439
Hong Kong 424
Woodbridge 400
Dublin 361
Ann Arbor 268
Beijing 217
Jinan 160
Verona 135
Houston 134
Lawrence 132
Princeton 132
Wilmington 126
Munich 121
Shenyang 97
Nanjing 88
The Dalles 79
New York 74
Helsinki 73
Los Angeles 73
Hebei 66
Buffalo 61
Tianjin 60
Columbus 52
Changsha 51
Redondo Beach 50
Zhengzhou 46
Sindelfingen 45
Haikou 44
São Paulo 43
Turku 42
Taiyuan 39
Milan 38
Hangzhou 37
Redwood City 35
Guangzhou 31
Ningbo 31
Taizhou 31
Frankfurt am Main 29
Nanchang 28
Seattle 26
Fuzhou 25
Santa Clara 24
Washington 24
Nuremberg 23
Rome 23
Tokyo 23
Redmond 22
San Francisco 22
Kent 21
Boardman 20
Brussels 20
Dong Ket 20
Jiaxing 20
Council Bluffs 19
Ho Chi Minh City 19
Rio de Janeiro 19
Toronto 18
Jakarta 17
Lomé 17
Norwalk 17
Chicago 16
Belo Horizonte 14
Bologna 14
Brasília 14
Dongguan 14
Seoul 14
Vienna 14
Hanoi 13
Johannesburg 13
Lanzhou 13
Amsterdam 12
Brooklyn 12
Montreal 12
Warsaw 12
Zurich 11
Boston 10
Campinas 10
Atlanta 8
Baghdad 8
Fairfield 8
London 8
Moscow 8
Charlotte 7
Dearborn 7
Lancaster 7
Phoenix 7
Stockholm 7
Xiangfen 7
Clearwater 6
Dhaka 6
Glasgow 6
Lappeenranta 6
Lima 6
Oakland 6
Quito 6
Totale 8.771
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 254
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 216
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 189
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 179
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 172
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 162
NF-κB as a target for pancreatic cancer therapy. 154
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 152
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 144
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer 142
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma 142
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 135
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 134
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 133
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 132
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 130
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 129
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance 129
Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells 129
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype 127
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 126
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma 126
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 125
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 125
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 124
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 123
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 122
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 121
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 120
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 120
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib 118
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 117
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer 117
Pancreatic Cancer: between bench and bedside. 116
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 115
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial 115
The development of PARP as a successful target for cancer therapy 114
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 114
Angiogenesis: A target for cancer therapy. 113
Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results 113
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 109
Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer 109
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 108
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 108
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 108
Histogram analysis of magnetic resonance images: evaluation of intra-tumoral heterogeneity and correlation with pathological findings in solid pancreatic tumors. 108
Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. 108
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data 107
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 106
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 105
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. 105
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 103
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 103
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 102
Rare secondary tumors of the pancreas 102
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 102
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer 101
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 100
CT texture analysis of ductal adenocarcinoma downstaged after chemotherapy 100
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers 99
EMT and Treatment Resistance in Pancreatic Cancer 99
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 97
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 94
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 93
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 93
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 93
The curious case of Gαs gain-of-function in neoplasia 93
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 92
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) 92
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 92
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinib ('Iressa') cooperatively inhibits growth and angiogenic factor expression in breast and prostate carcinoma cells. 91
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer 91
ESGAR 2018 Book of Abstracts 91
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity 91
Toll-Like Receptor 9 Agonists for Cancer Therapy 91
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells 90
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus 90
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 90
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis 89
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 89
Key cancer cell signal transduction pathways as therapeutic targets. 88
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 88
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion 88
Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC). 87
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy 87
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 87
TGF-beta-activated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic cancer chemoresistance 86
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 86
The novel poly(ADP-ribose) polymerase (PARP)-1 inhibitor, BSI-401, has anti tumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer 85
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 85
The role of the oncologist in the diagnosis and management of malignant cystic neoplasms 84
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma 84
Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts 83
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 83
Permissive State of EMT: The Role of Immune Cell Compartment 83
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells 82
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies 82
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 81
Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. 80
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 79
Totale 11.090
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.583
article - articoli 49.156
book - libri 0
conference - conferenze 7.026
curatela - curatele 0
other - altro 378
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.023
Totale 115.166
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021756 0 0 0 138 129 134 8 69 34 58 107 79
2021/20221.221 87 433 13 167 15 15 9 62 38 22 68 292
2022/20232.311 180 234 221 357 209 553 28 138 293 23 49 26
2023/20241.331 43 101 94 123 164 183 116 166 15 71 198 57
2024/20253.233 167 191 110 510 138 99 177 160 491 200 311 679
2025/20261.871 686 430 685 70 0 0 0 0 0 0 0 0
Totale 14.080